Developing regulatory T cell therapies to manage immune tolerance.

Regatta Bio is developing next-generation Treg therapies to overcome limitations in current approaches, targeting diseases such as stem cell and solid organ transplantation and autoimmune disorders. Their pipeline includes ex vivo expanded Tregs with low dose IL-2 for chronic Graft-versus-Host Disease and engineered IL-2-independent OX40L-CAR Tregs for enhanced immunosuppressant resistance.